diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-3602diaendo-3602Research ArticleСтатьиArticlesСовременные подходы к базисно-болюсной инсулинотерапии с использованием аналогов инсулина гларгин и глулизин в разных возрастных группахModern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groupsВолеводзНаталья НикитичнаVolevodzNatalya Nikitichnannvolevodz@mail.ruЛаптевДмитрий НикитичLaptevDmitriy Nikitich-ШестаковаМарина ВладимировнаShestakovaMarina Vladimirovna-ФГБУ Эндокринологический научный центр, МоскваEndocrinology Research Centre, Moscow201315032013161№1 (2013)8390Copyright © Волеводз Н.Н., Лаптев Д.Н., Шестакова М.В., 20132013Волеводз Н.Н., Лаптев Д.Н., Шестакова М.В.Volevodz N.N., Laptev D.N., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/3602

Исследование DCCT (Diabetes Control and Complications Trial) продемонстрировало, что интенсифицированная инсулино- терапия с введением инсулина как в режиме многократных инъекций инсулина (MDI), так и постоянной подкожной инфу- зии инсулина (CSII) способствует значительному снижению риска развития и прогрессирования осложнений у пациентов с сахарным диабетом 1 типа (СД1) по сравнению с традиционной инсулинотерапией. Аналоги инсулина имеют лучшие фармакокинетические и фармакодинамические характеристики по сравнению с человеческими инсулинами. Эти харак- теристики предоставляют преимущества для лечения СД, в частности с точки зрения достижения оптимального уровня гликемического контроля и снижения риска гипогликемии.Обзор посвящен особенностям инсулинотерапии аналогами человеческого инсулина гларгин (Лантус?) и глулизин (Апидра?). Авторами проанализированы результаты проведенных к настоящему времени клинических исследований применения инсу- лина гларгин и глулизин у детей, подростков и взрослых. Рассмотрены фармакоэкономические аспекты и вопросы титра- ции дозы инсулина гларгин и глулизин.

DCCT (Diabetes Control and Complications Trial) study established that intensified insulin therapy in multiple daily injections (MDI) or continuous insulin infusion (CSII) regimens substantially reduce both development and progression of complications in patients with type 1 diabetes mellitus (T1DM) as compared to conventional insulin therapy. Insulin analogues possess better pharmacokinetic and pharmacodynamic characteristics than unmodified human insulin agents. These characteristics are beneficial for management of diabetes mellitus, allowing better glycemic outcomes with lower incidence of hypoglycemia.Current review discusses specifics of therapy with glargine (Lantus?) and glulisine (Apidra?) insulin analogues. Authors analyzed available to date results from corresponding clinical trials in children, adolescents and adults. Pharmacoeconomic aspects and matters of dosage of glargine and glulisine are further addressed.

сахарный диабетаналоги инсулинагипогликемияdiabetes mellitusinsulin analogueshypoglycemiaReferencesDiabetes Control and Complications Trial Research Group. The ef- fect of intensive treatment of diabetes on the development and pro- gression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977–986.Diabetes Control and Complications Trial Research Group. The ef- fect of intensive treatment of diabetes on the development and pro- gression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977–986.Hirsch IB. Insulin analogues. N Engl J Med. 2005 Jan 13;352(2):174–183.Hirsch IB. Insulin analogues. N Engl J Med. 2005 Jan 13;352(2):174–183.Coppolino R, Coppolino S, Villari V. Study of the aggregation of insulin glargine by light scattering. J Pharm Sci. 2006 May;95(5):1029–1034.Coppolino R, Coppolino S, Villari V. Study of the aggregation of insulin glargine by light scattering. J Pharm Sci. 2006 May;95(5):1029–1034.ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000 Oct;23(10):1467–1471.ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000 Oct;23(10):1467–1471.Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002 May 15;287(19):2563–2569.Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002 May 15;287(19):2563–2569.Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultane- ously for the effect of gender, age, and puberty. J Clin Endocri- nol Metab. 2001 Dec;86(12):5870–5876.Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultane- ously for the effect of gender, age, and puberty. J Clin Endocri- nol Metab. 2001 Dec;86(12):5870–5876.Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005 Jan–Feb;11(1):55–64.Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005 Jan–Feb;11(1):55–64.Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990 Jan;33(1):52–59.Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990 Jan;33(1):52–59.Kobayashi K, Amemiya S, Sawanobori E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care. 1997 Sep;20(9):1442–1447.Kobayashi K, Amemiya S, Sawanobori E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care. 1997 Sep;20(9):1442–1447.Holterhus PM, Odendahl R, Oesingmann S, Lepler R, Wagner V, Hiort O, Holl R; German/Austrian DPV Initiative; German Pediatric CSII Working Group. Classification of distinct baseline insulin infusion patterns in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion therapy. Diabetes Care. 2007 Mar;30(3):568–573.Holterhus PM, Odendahl R, Oesingmann S, Lepler R, Wagner V, Hiort O, Holl R; German/Austrian DPV Initiative; German Pediatric CSII Working Group. Classification of distinct baseline insulin infusion patterns in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion therapy. Diabetes Care. 2007 Mar;30(3):568–573.Löhr B, Siegmund R. Ultradian and circadian rhythms of sleep- wake and food-intake behavior during early infancy. Chrono- biol Int. 1999 Mar;16(2):129–148.Löhr B, Siegmund R. Ultradian and circadian rhythms of sleep- wake and food-intake behavior during early infancy. Chrono- biol Int. 1999 Mar;16(2):129–148.Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Tor- lone E, Scionti L, Bolli GB. ntensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin ana- log at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003 May;26(5):1490–1496.Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Tor- lone E, Scionti L, Bolli GB. ntensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin ana- log at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003 May;26(5):1490–1496.Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Sci- onti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Dia- bet Med. 2004 Nov;21(11):1213–1220.Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Sci- onti L, Perriello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Dia- bet Med. 2004 Nov;21(11):1213–1220.Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000 Nov;23(11):1666–1671.Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000 Nov;23(11):1666–1671.Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000 May;23(5):639–643.Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000 May;23(5):639–643.Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A; European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005 Nov–Dec;21(6):545–553.Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A; European Insulin Glargine Study Group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005 Nov–Dec;21(6):545–553.Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, Mc- Nally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes — the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract. 2007 Aug;77(2):215–222.Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, Mc- Nally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes — the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract. 2007 Aug;77(2):215–222.Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005 Sep;35(9):536–542.Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005 Sep;35(9):536–542.Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571–579. DOI: 10.1016/j.numecd.2008.05.003.Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571–579. DOI: 10.1016/j.numecd.2008.05.003.Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004 Jan–Feb;10(1):10–17.Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004 Jan–Feb;10(1):10–17.Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142–2148.Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142–2148.Schreiber S, Landgraf W, Bohler S. Efficacy and tolerability of insulin glargine in ICT. Diabetes, Stoffwechsel und Herz. 2009;(8):91–98.Schreiber S, Landgraf W, Bohler S. Efficacy and tolerability of insulin glargine in ICT. Diabetes, Stoffwechsel und Herz. 2009;(8):91–98.Daikeler R, Hogy B, Donaubauer B. Effects of an intensified insulin therapy (ICT) with insulin glargine and insulin glulisine on patient reported outcomes (PRO) in diabetes mellitus. Diabetologie und Stoffwechsel. 2007;(2):308–314.Daikeler R, Hogy B, Donaubauer B. Effects of an intensified insulin therapy (ICT) with insulin glargine and insulin glulisine on patient reported outcomes (PRO) in diabetes mellitus. Diabetologie und Stoffwechsel. 2007;(2):308–314.Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010 Jan;27(1):72–78. DOI: 10.1111/j.1464– 5491.2009.02867.x.Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010 Jan;27(1):72–78. DOI: 10.1111/j.1464– 5491.2009.02867.x.Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care. 2001 Sep;24(9):1541–1546.Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care. 2001 Sep;24(9):1541–1546.Campbell I. Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia? Diabet Med. 1991 Jan;8(1):3–4.Campbell I. Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia? Diabet Med. 1991 Jan;8(1):3–4.Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991 Jan;8(1):49–58.Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991 Jan;8(1):49–58.Рябыкина ГВ, Лаптев ДН, Сеид-Гуссейнов АА. Изменение длительности интервала QT у детей и подростков, больных сахарным диабетом 1-го типа. Кардиология. 2007;(12):35–39.Рябыкина ГВ, Лаптев ДН, Сеид-Гуссейнов АА. Изменение длительности интервала QT у детей и подростков, больных сахарным диабетом 1-го типа. Кардиология. 2007;(12):35–39.Лаптев ДН, Рябыкина ГВ, Соболев АВ, Кириллов КК, Сеид- Гусейнов АА. Связь гликемии и длительности интервала QT с двигательной активностью у детей и подростков, больных сахарным диабетом 1 типа. Проблемы эндокринологии. 2010;55(6):24–31.Лаптев ДН, Рябыкина ГВ, Соболев АВ, Кириллов КК, Сеид- Гусейнов АА. Связь гликемии и длительности интервала QT с двигательной активностью у детей и подростков, больных сахарным диабетом 1 типа. Проблемы эндокринологии. 2010;55(6):24–31.Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571–579. DOI: 10.1016/j.numecd.2008.05.003.Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571–579. DOI: 10.1016/j.numecd.2008.05.003.Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005 Jan–Feb;11(1):55–64.Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract. 2005 Jan–Feb;11(1):55–64.Koivisto VA, Yki-Järvinen H, Helve E, Karonen SL, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986 Jan;35(1):78–82.Koivisto VA, Yki-Järvinen H, Helve E, Karonen SL, Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 1986 Jan;35(1):78–82.Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, Mochizuki M, Kobayashi K, Cho H, Ohyama K, Amemiya S, Nakazawa S. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: differences in the dawn phenomenon between insulin regimens. Exp Clin Endocrinol Diabetes. 2010 Mar;118(3):195–199. DOI: 10.1055/s-0029-1239518.Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, Mochizuki M, Kobayashi K, Cho H, Ohyama K, Amemiya S, Nakazawa S. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: differences in the dawn phenomenon between insulin regimens. Exp Clin Endocrinol Diabetes. 2010 Mar;118(3):195–199. DOI: 10.1055/s-0029-1239518.Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006 Aug;23(8):879–886.Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006 Aug;23(8):879–886.Conget I, Storms F, Rodriguez J, Leperlier C, Davies M, Gomis R. Changing from prior premix insulin regimen to insulin glargine in patients with type 1 diabetes: results from the AT.LANTUS trial [abstract 83]. Diabetologia. 2004; (47): A33.Conget I, Storms F, Rodriguez J, Leperlier C, Davies M, Gomis R. Changing from prior premix insulin regimen to insulin glargine in patients with type 1 diabetes: results from the AT.LANTUS trial [abstract 83]. Diabetologia. 2004; (47): A33.Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care. 2001 Nov;24(11):2005–2006.Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care. 2001 Nov;24(11):2005–2006.Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr. 2008 Oct;153(4):547–553. DOI: 10.1016/j.jpeds.2008.04.063.Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr. 2008 Oct;153(4):547–553. DOI: 10.1016/j.jpeds.2008.04.063.Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005 Jan-Feb;11(1):11–7.Garg SK, Rosenstock J, Ways K. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract. 2005 Jan-Feb;11(1):11–7.Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R.Efficacy and safety of insulin glulisine in patients with type 1 diabetes.Horm Metab Res. 2005 Nov;37(11):702–7.Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R.Efficacy and safety of insulin glulisine in patients with type 1 diabetes.Horm Metab Res. 2005 Nov;37(11):702–7.Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y. Efficacy and safety of insulin glulisine in Japanese patients with type 1 dia- betes mellitus. Diabetes Obes Metab. 2009 Sep;11(9):891–9.Kawamori R, Kadowaki T, Ishii H, Iwasaki M, Iwamoto Y. Efficacy and safety of insulin glulisine in Japanese patients with type 1 dia- betes mellitus. Diabetes Obes Metab. 2009 Sep;11(9):891–9.Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Sou- hami E, Danne T. Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal bolus regimen in children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2011 Mar;13(3):327–334. DOI: 10.1089/dia.2010.0072.Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Sou- hami E, Danne T. Efficacy and safety of insulin glulisine versus insulin lispro as part of a basal bolus regimen in children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2011 Mar;13(3):327–334. DOI: 10.1089/dia.2010.0072.Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005 Sep;28(9):2100–2105.Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005 Sep;28(9):2100–2105.Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006 Jun;38(6):429–433.Hoogma RP, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res. 2006 Jun;38(6):429–433.Bierwirth R, Dippel FW, Kostev K, Fuchs S, Kotowa W. Resource utilization and diabetes-related treatment costs of type-1-diabetics treated with ICT based on insulin glargine, insulin detemir or NPH insulin in Germany. Poster 46th EASD Annual Meeting, 20th–24th September 2010, Stockholm.Bierwirth R, Dippel FW, Kostev K, Fuchs S, Kotowa W. Resource utilization and diabetes-related treatment costs of type-1-diabetics treated with ICT based on insulin glargine, insulin detemir or NPH insulin in Germany. Poster 46th EASD Annual Meeting, 20th–24th September 2010, Stockholm.Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW; German working group for insulin pump treatment in paediatric patients. German working group for insulin pump treatment in paediatric patients. Pediatr Dia- betes. 2008 Dec;9(6):590–595. DOI: 10.1111/j.1399- 5448.2008.00416.x.Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW; German working group for insulin pump treatment in paediatric patients. German working group for insulin pump treatment in paediatric patients. Pediatr Dia- betes. 2008 Dec;9(6):590–595. DOI: 10.1111/j.1399- 5448.2008.00416.x.Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care. 2009 Jul;32(7):1170–1176. DOI: 10.2337/dc08-1874.Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care. 2009 Jul;32(7):1170–1176. DOI: 10.2337/dc08-1874.Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 Nov;26(11):3080–3086.Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003 Nov;26(11):3080–3086.Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282–1288.Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282–1288.Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab. 2011 Nov;13(11):1020-1027. DOI: 10.1111/j.1463- 1326.2011.01459.x.Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab. 2011 Nov;13(11):1020-1027. DOI: 10.1111/j.1463- 1326.2011.01459.x.

The authors declare that there are no conflicts of interest present.